Literature DB >> 8368547

Myocardial uptake of bupivacaine: II. Pharmacokinetics and pharmacodynamics of bupivacaine enantiomers in the isolated perfused rabbit heart.

J X Mazoit1, O Boïco, K Samii.   

Abstract

The enantiomers of a racemic drug generally differ in their pharmacokinetic and/or pharmacodynamic properties. Because bupivacaine is a mixture of two optical isomers known to exert different toxic properties on isolated nerve preparations, we decided to use an isolated rabbit heart model with constant coronary inflow to compare the myocardial uptake kinetics of the R(+)-, S(-)-enantiomers and the racemic mixture of bupivacaine. The increase in QRS duration was also measured, and the inflow concentration-effect relationship was analyzed for the three drugs. The racemic and the two enantiomers of bupivacaine exhibited similar myocardial pharmacokinetics with a two-compartment profile for all hearts except one. All drugs showed a rapid decrease in the outflow concentration when drug administration was discontinued. The tissue/perfusate concentration ratio at steady state was similar for the three drugs. QRS widening, as well as the occurrence of severe arrhythmias, was much less pronounced in the hearts receiving the S(-) isomer than in the hearts receiving the R(+) isomer or the racemic mixture. Despite the occurrence of arrhythmias, QRS widening was adequately modelled with an Emax model. C50, the inflow perfusate concentration producing half Emax (maximal theoretical increase in QRS duration) was the same for all three drugs. The authors conclude that the S(-)-bupivacaine exerts less detrimental effects on the isolated heart of the rabbit perfused at a constant coronary flow with protein-free buffer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368547

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  18 in total

Review 1.  Anaesthesia.

Authors:  A J Fox; D J Rowbotham
Journal:  BMJ       Date:  1999-08-28

Review 2.  [Toxicology of local anesthetics. Clinical, therapeutic and pathological mechanisms].

Authors:  W Zink; B M Graf
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

3.  A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers.

Authors:  H Bardsley; R Gristwood; H Baker; N Watson; W Nimmo
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

4.  Comparison of 0.25% levobupivacaine and 0.25% bupivacaine for posterior approach interscalene brachial plexus block.

Authors:  Semih Baskan; Vildan Taspinar; Levent Ozdogan; Kemal Yetis Gulsoy; Gulcan Erk; Bayazit Dikmen; Nermin Gogus
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

5.  Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep.

Authors:  D H Chang; L A Ladd; S Copeland; M A Iglesias; J L Plummer; L E Mather
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 6.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

Review 7.  Levobupivacaine: a review of its pharmacology and use as a local anaesthetic.

Authors:  R H Foster; A Markham
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

8.  Pharmacokinetics of bupivacaine enantiomers in sheep: influence of dosage regimen and study design.

Authors:  L E Mather; A J Rutten; J L Plummer
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

Review 9.  Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions.

Authors:  J M Thomas; S A Schug
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

10.  Levobupivacaine vs. bupivacaine for third molar surgery: quality of anaesthesia, postoperative analgesia and local vascular effects.

Authors:  Denis Brajkovic; Bozidar Brkovic; Marija Milic; Vladimir Biocanin; Elena Krsljak; Dragica Stojic
Journal:  Clin Oral Investig       Date:  2013-10-06       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.